WMS Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

WMS Partners’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-8,500	Closed	-$206K	–	262
2022 Q1	$206K	Buy	+8,500	New	+$206K	0.03%	245

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

WMS Partners's ACAD Position: Q2 2022 in Review

WMS Partners sold out of Acadia Pharmaceuticals (ACAD) in Q2 2022, closing a stake of 8,500 shares — an estimated $206K sold.

WMS Partners first reported a position in ACAD in Q1 2022 and held it in 1 quarter. The position peaked at $206K in Q1 2022. 246 funds tracked by Wall St. Rank hold ACAD as of Q2 2022.

WMS Partners reported no remaining Acadia Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
WMS Partners sold 8,500 Acadia Pharmaceuticals shares in Q2 2022, an estimated $206K.
WMS Partners first reported a position in Acadia Pharmaceuticals in Q1 2022 and held it in 1 quarter.
WMS Partners's Acadia Pharmaceuticals position peaked at $206K in Q1 2022.
246 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2022.

Based on WMS Partners's 13F filing for Q2 2022, filed 5 Aug 2022.